|
Synonyms: PF-04383119 | PF04383119 | RN624
Compound class:
Antibody
Comment: Tanezumab is an investigational monoclonal antibody targeting nerve growth factor (NGF). NGF is a neurotrophin that regulates the development and survival of a select population of neurons through the binding and activation of the neurotrophic receptor tyrosine kinase 1 (TrkA receptor). Elevated levels of NGF have been associated with painful pathologies including diabetic neuropathy, fibromyalgia and osteoarthritis, and cancer apin. Inhibition of NGF signalling has been explored for anti-pain potential.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical sequences are claimed in patent US7449616. |
| No information available. |
Summary of Clinical Use  |
| Tanezumab has been evaluated in Phase 3 clinical trials as a potential treatment for multiple pain indications [1,4,11] including osteoarthritis (OA) pain [2] and cancer-associated pain [3]. Development of this antibody has been disrupted due to the high incidence of rapidly progressive OA (RPOA) in subjects receiving anti-NGF antibodies (especially in those receiving concomittant NSAID therapy) [5]. RPOA had derailed earlier studies of NGF inhibitors. A meta-analysis of nine publications covering 10 studies was published by Hu et al., (2021) [6]. This analyisis was designed to determine the drug dose that provides the optimum risk/benefit ratio. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02528253 | A Phase 3 Study of Tanezumab for Chronic Low Back Pain | Phase 3 Interventional | Pfizer | 7 | |
| NCT04163419 | Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis | Phase 2 Interventional | Massachusetts General Hospital | ||
| NCT00001693 | Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers | Phase 1 Interventional | National Institutes of Health Clinical Center (CC) | 9-10 | |
| NCT01087203 | A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy | Phase 2 Interventional | Pfizer | This study was put on clinical hold by the FDA for potential safety issues, and was subsequently terminated in November 2010. | 1 |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | Phase 3 Interventional | Pfizer | 3 | |
